当前位置:首页 - 行情中心 - 上海医药(601607) - 财务分析 - 现金流量表

上海医药

(601607)

  

流通市值:339.75亿  总市值:651.41亿
流通股本:19.32亿   总股本:37.03亿

现金流量表

报告期2023-12-312023-09-302023-06-302023-03-31
公司类型通用通用通用通用
一、经营活动产生的现金流量:
销售商品、提供劳务收到的现金283,639,391,269.47204,290,588,465.32134,194,612,093.0263,290,789,704.39
收到的税费返还113,743,387.01155,184,151.380,136,280.3696,565,172.08
收到其他与经营活动有关的现金3,030,275,784.492,726,507,5461,927,991,899.69887,443,149.47
经营活动现金流入的平衡项目0000
经营活动现金流入小计286,783,410,440.97207,172,280,162.62136,202,740,273.0764,274,798,025.94
购买商品、接受劳务支付的现金251,978,264,993.59179,260,234,405.85119,292,485,211.1258,532,385,462.83
支付给职工以及为职工支付的现金9,896,044,336.216,660,639,066.44,995,677,959.82,595,719,194.21
支付的各项税费7,497,835,891.886,089,479,083.774,003,756,1732,010,859,495.28
支付其他与经营活动有关的现金12,179,745,492.1912,859,466,996.926,272,396,981.233,759,156,285.91
经营活动现金流出的平衡项目0000
经营活动现金流出小计281,551,890,713.87204,869,819,552.94134,564,316,325.1566,898,120,438.23
经营活动产生的现金流量净额平衡项目0000
经营活动产生的现金流量净额5,231,519,727.12,302,460,609.681,638,423,947.92-2,623,322,412.29
二、投资活动产生的现金流量:
收回投资收到的现金26,878,643,654.9923,578,630,752.8512,543,612,200.99,226,650,000
取得投资收益收到的现金982,754,122.37714,044,154.09315,481,265.5116,045,884.59
处置固定资产、无形资产和其他长期资产收回的现金净额179,147,386.52147,026,248.694,399,109.5520,215,544.66
处置子公司及其他营业单位收到的现金净额500,000--5,616,030.38
收到的其他与投资活动有关的现金1,268,304,839.071,193,770,126.36830,122,037.65195,781,000
投资活动现金流入的平衡项目0000
投资活动现金流入小计29,309,350,002.9525,633,471,281.913,783,614,613.69,564,308,459.63
购建固定资产、无形资产和其他长期资产支付的现金2,970,610,219.582,284,612,415.551,503,729,823.71692,118,377.2
投资支付的现金27,376,650,00025,376,650,00014,326,650,00010,726,650,000
取得子公司及其他营业单位支付的现金357,077,909.96156,753,465.02150,983,465.02132,075,928.25
支付其他与投资活动有关的现金1,096,884,711.93815,004,988.47416,901,892.77119,681,620.89
投资活动现金流出的平衡项目0000
投资活动现金流出小计31,801,222,841.4728,633,020,869.0416,398,265,181.511,670,525,926.34
投资活动产生的现金流量净额平衡项目0000
投资活动产生的现金流量净额-2,491,872,838.52-2,999,549,587.14-2,614,650,567.9-2,106,217,466.71
三、筹资活动产生的现金流量:
吸收投资收到的现金354,277,173.14355,191,273.12314,359,849.08156,812,130.67
其中:子公司吸收少数股东投资收到的现金247,857,740.02248,771,840209,604,056.26139,267,640
取得借款收到的现金64,196,587,074.8946,823,616,396.5733,896,402,612.8220,235,395,821.94
发行债券收到的现金14,996,763,333.3211,997,529,999.9911,997,529,999.995,999,608,333.33
收到其他与筹资活动有关的现金164,138,149.09281,237,975.6575,627,140.2395,630,130.83
筹资活动现金流入平衡项目0000
筹资活动现金流入小计79,711,765,730.4459,457,575,645.3346,283,919,602.1226,487,446,416.77
偿还债务支付的现金72,338,337,862.0250,499,551,661.8538,392,377,994.1120,411,095,330.39
分配股利、利润或偿付利息支付的现金4,915,917,995.464,356,294,844.111,393,830,629.75971,885,204.72
其中:子公司支付给少数股东的股利、利润934,712,519.71708,973,897.97482,102,728.33333,773,431.04
支付其他与筹资活动有关的现金2,225,658,982.231,805,788,030.991,366,090,423.32791,417,137.74
筹资活动现金流出平衡项目0000
筹资活动现金流出小计79,479,914,839.7156,661,634,536.9541,152,299,047.1822,174,397,672.85
筹资活动产生的现金流量净额平衡项目0000
筹资活动产生的现金流量净额231,850,890.732,795,941,108.385,131,620,554.944,313,048,743.92
四、汇率变动对现金及现金等价物的影响-5,580,083.93-60,841,645.22-948,933.06-12,668,704.92
现金及现金等价物净增加额平衡项目0000
五、现金及现金等价物净增加额2,965,917,695.382,038,010,485.74,154,445,001.9-429,159,840
加:期初现金及现金等价物余额24,533,891,305.8224,533,891,305.8224,533,891,305.8224,533,891,305.82
期末现金及现金等价物余额平衡项目0000
期末现金及现金等价物余额27,499,809,001.226,571,901,791.5228,688,336,307.7224,104,731,465.82
补充资料:
净利润5,166,570,284.26-3,417,001,019.98-
资产减值准备561,277,474.11--66,099,386.5-
固定资产和投资性房地产折旧1,115,950,314.3-554,595,413.55-
无形资产摊销380,603,239.09-188,936,714.96-
长期待摊费用摊销192,328,518.62-99,430,291.9-
处置固定资产、无形资产和其他长期资产的损失-92,475,307.03--73,745,726.6-
公允价值变动损失-404,731,380.72--196,842,384.45-
财务费用1,862,945,397.89-963,410,193.84-
投资损失-175,997,919.6-65,481,685.24-
递延所得税-194,790,792.3--130,458,867.13-
其中:递延所得税资产减少-146,609,422.15--63,856,309.3-
递延所得税负债增加-48,181,370.15--66,602,557.83-
存货的减少-2,303,791,595.46-1,457,633,256.6-
经营性应收项目的减少-6,432,413,771.71--10,544,239,123.58-
经营性应付项目的增加4,585,509,346.07-5,230,732,160.03-
现金的期末余额27,499,809,001.2-28,688,336,307.72-
减:现金的期初余额24,533,891,305.82-24,533,891,305.82-
公告日期2024-03-292023-10-282023-08-302023-04-27
审计意见(境内)标准无保留意见
TOP↑